Vincerx Pharma, Inc.
VINC
$0.05
-$0.005-9.09%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.54% | -0.43% | -22.53% | -29.46% | -31.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.14% | -31.79% | -43.79% | -46.55% | -44.52% |
| Operating Income | 28.14% | 31.79% | 43.79% | 46.55% | 44.52% |
| Income Before Tax | 40.31% | 25.11% | 41.83% | 48.11% | 38.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.31% | 25.11% | 41.83% | 48.11% | 38.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.31% | 25.11% | 41.83% | 48.11% | 38.02% |
| EBIT | 28.14% | 31.79% | 43.79% | 46.55% | 44.52% |
| EBITDA | 28.19% | 31.83% | 43.83% | 46.59% | 44.55% |
| EPS Basic | 68.43% | 43.77% | 49.08% | 49.88% | 39.03% |
| Normalized Basic EPS | 71.45% | 46.61% | 49.08% | 48.64% | 36.47% |
| EPS Diluted | 68.43% | 43.77% | 49.08% | 49.88% | 39.03% |
| Normalized Diluted EPS | 71.45% | 46.61% | 49.08% | 48.64% | 36.47% |
| Average Basic Shares Outstanding | 107.33% | 49.99% | 22.83% | 11.34% | 1.52% |
| Average Diluted Shares Outstanding | 107.33% | 49.99% | 22.83% | 11.34% | 1.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |